Benjamin Edwards Inc. lifted its holdings in AbbVie Inc. (NYSE:ABBV – Free Report) by 1.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 331,067 shares of the company’s stock after buying an additional 3,745 shares during the quarter. AbbVie accounts for 0.8% of Benjamin Edwards Inc.’s portfolio, making the stock its 17th biggest holding. Benjamin Edwards Inc.’s holdings in AbbVie were worth $86,624,000 as of its most recent SEC filing.
Other hedge funds also recently added to or reduced their stakes in the company. CacheTech Inc. raised its stake in shares of AbbVie by 13.1% during the third quarter. CacheTech Inc. now owns 5,213 shares of the company’s stock valued at $1,364,000 after purchasing an additional 603 shares during the period. First Trust Advisors LP raised its stake in AbbVie by 16.2% during the third quarter. First Trust Advisors LP now owns 930,220 shares of the company’s stock worth $243,336,000 after acquiring an additional 129,402 shares during the period. BNP Paribas lifted its holdings in AbbVie by 15.2% in the third quarter. BNP Paribas now owns 91,694 shares of the company’s stock worth $24,025,000 after acquiring an additional 12,098 shares during the last quarter. Allianz SE lifted its holdings in AbbVie by 5.2% in the third quarter. Allianz SE now owns 88,139 shares of the company’s stock worth $23,056,000 after acquiring an additional 4,367 shares during the last quarter. Finally, Coastwise Capital Group LLC boosted its stake in AbbVie by 2.3% in the third quarter. Coastwise Capital Group LLC now owns 1,705 shares of the company’s stock valued at $446,000 after acquiring an additional 39 shares during the period. 70.23% of the stock is owned by hedge funds and other institutional investors.
Top AbbVie Stories
Here are a few of the latest stories about ABBV:
- Positive Sentiment: Piper Sandler raised its price target to $349 from $303 and maintained an Overweight rating, implying about 23% upside from the prior close. Article: AbbVie Is Near Its High. Piper Sandler Sees Another 23%
- Positive Sentiment: AbbVie partnered with DISCO Pharmaceuticals to discover next-generation bispecific cancer therapies for solid tumors. DISCO could receive up to $2.5 billion in milestone payments, while AbbVie has options to license selected programs; the deal adds pipeline potential, though returns depend on successful research and development. Article: DISCO, AbbVie Sign AND-Gated Bispecific Deal Worth Up to $2.5B
- Negative Sentiment: ETFs were net sellers of AbbVie shares, with reported net outflows of $124.5 million on Nov. 18, indicating near-term fund selling pressure. Article: ETFs Are Net Sellers of AbbVie
AbbVie Trading Up 0.9%
AbbVie (NYSE:ABBV – Get Free Report) last issued its earnings results on Friday, October 30th. The company reported $3.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.73 by $0.09. AbbVie had a net margin of 15.67% and a negative return on equity of 450.55%. The company had revenue of $17.40 billion during the quarter, compared to analyst estimates of $17.32 billion. During the same quarter last year, the business posted $1.86 EPS. The company’s revenue for the quarter was up 10.3% on a year-over-year basis. On average, sell-side analysts predict that AbbVie Inc. will post 13.99 EPS for the current year.
AbbVie Increases Dividend
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, February 16th. Investors of record on Friday, January 15th will be paid a dividend of $1.82 per share. This represents a $7.28 annualized dividend and a yield of 2.5%. The ex-dividend date is Friday, January 15th. This is a positive change from AbbVie’s previous quarterly dividend of $1.73. AbbVie’s dividend payout ratio is currently 119.10%.
Insiders Place Their Bets
In other news, EVP Jeffrey Stewart sold 40,619 shares of the business’s stock in a transaction that occurred on Monday, November 9th. The stock was sold at an average price of $293.60, for a total transaction of $11,925,738.40. Following the sale, the executive vice president directly owned 83,171 shares in the company, valued at approximately $24,419,005.60. The trade was a 32.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.06% of the stock is currently owned by company insiders.
Wall Street Analyst Weigh In
A number of analysts have recently weighed in on ABBV shares. Piper Sandler set a $349.00 price target on AbbVie and gave the stock an “overweight” rating in a research report on Wednesday. Barclays raised their target price on AbbVie from $325.00 to $335.00 and gave the company an “overweight” rating in a research report on Monday, November 16th. BMO Capital Markets set a $315.00 target price on AbbVie in a report on Wednesday, November 4th. The Goldman Sachs Group raised their target price on AbbVie from $258.00 to $294.00 and gave the company a “neutral” rating in a research note on Friday, October 23rd. Finally, Canaccord Genuity Group lifted their target price on AbbVie from $290.00 to $338.00 and gave the stock a “buy” rating in a report on Monday, November 2nd. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, AbbVie currently has an average rating of “Moderate Buy” and a consensus target price of $299.62.
AbbVie Company Profile
AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.
Featured Stories
- Five stocks we like better than AbbVie
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
